Tag: BRCA

8
Jul 2019

Bionest

News from ASCO: Part 1 

As we previously wrote, ASCO’s focus this year was on driving the benefits of precision medicine approaches in oncology to more patients. This was reflected in several ways in the news coming out of the conference, including:   Progress Against Important, Difficult-to-Target Biomarkers   The ASCO news was particularly good this year for patients with...
6
Dec 2018

Bionest

Report on ESMO 2018 – Part Two

We recently returned from the European Society for Medical Oncology (ESMO) meeting where conference news highlighted the increased movement of targeted therapies and immunotherapies into adjuvant and early-stage cancer settings. Read our earlier report on combination therapy trials in melanoma, colon cancer and breast cancer, including triple-negative breast cancer. Here, we cover other targeted therapies....
5
Feb 2018

Bionest

Lynparza — Extending Cancer Treatment Based on Underlying Genetic Cause

On January 12, the U.S. Food and Drug Administration approved Lynparza (olaparib), the PARP inhibitor partnered by AstraZeneca and Merck, for the treatment of BRCA-mutated, HER2-negative advanced metastatic breast cancer.   The FDA’s action adds another cancer type for Lynparza; in late 2014 it was the first PARP inhibitor to be approved for use in...